摘要
口腔扁平苔藓(orallichenplanus,OLP)是临床较为常见的慢性疾病,多与免疫功能及黏膜组织慢性炎症相关。目前,其发病机制不明确,常用治疗药物包括皮质类固醇、免疫抑制剂、维A酸和免疫调节剂等,但尚无特效疗法。近年来,生物制剂不断涌现,为难治性OLP患者提供了新的治疗方式。对生物制剂治疗OLP的分类、机制、用药剂量、治疗效果及不良反应进行了综述,并对其发展前景进行了展望。
Oral lichen planus(OLP)is a common chronic clinical disease,mostly associated with immune function and chronic inflammation of mucosal tissues.At present,its pathogenesis is unclear.Commonly used therapeutic drugs include corticosteroids,immunosuppressants,retinoids,and immunomodulators,but there is no specific therapy.In recent years,the continuous emergence of biologics has provided a new treatment method for patients with refractory OLP.This article reviews the classification,mechanism,dosage,therapeutic effect,and adverse reactions of biologics in the treatment of OLP,and prospects their development prospects.
作者
汪文厅
Wang Wenting(Dental Hospital Affiliated to Zhejiang University School of Medicine,Hangzhou,Zhejiang 310000)
出处
《科技与健康》
2025年第13期97-100,共4页
Technology and Health
